Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening

Archives of Disease in Childhood

Volumn 92, Issue 10, 2007, Pages 842-846

  Cipolli, Marco ^a   Castellani, Carlo ^a   Wilcken, Bridget ^b   Massie, John ^b   McKay, Karen ^b   Gruca, Margie ^c   Tamanini, Anna ^a   Assael, Maurice Baroukh ^a   Gaskin, Kevin ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLIPASE; TRYPSIN;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME RELEASE; FEMALE; GENE MUTATION; HUMAN; IMMUNOREACTIVITY; INFANT; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MUTATIONAL ANALYSIS; NEWBORN SCREENING; PANCREAS FUNCTION; PANCREAS INSUFFICIENCY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCREENING TEST;

CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; NEONATAL SCREENING; NUTRITION DISORDERS; NUTRITIONAL STATUS; PHENOTYPE; PREGNANCY;

EID: 35148849091     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.107581     Document Type: Article

References (35)

1. Crossley JR, Smith PA, Gluckman PD, et al. Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots. Clin Chim Acta 1981;113:111-21.
2. Wilcken B, Brown AR, Urwin R, et al. Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr 1983;102:383-7.
3. Ad Hoc Committee Task Force on Neonatal Screening, Cystic Fibrosis Foundation. Neonatal screening for cystic fibrosis: position paper. Pediatrics 1983;72:741-5.
4. Waters DL, Dorney SFA, Gaskin KJ, et al. Pancreatic function in infants identified as having cystic fibrosis in a neonatal program. N Engl J Med 1990;332:303-8.
5. Gaskin K, Waters D, Dorney S, et al. Assessment of pancreatic function in screened infants with cystic fibrosis. Pediatr Pulmonol Suppl 1991;7:69-71.
6. Gaskin K, Gruca M, Nouri-Sorkhabi MC, et al. Exocrine pancreatic disease in cystic fibrosis: changing phenotype with age. Pediatr Pulmonol Suppl 2003;25:142-3.
7. Ahmed M, Corey M, Forstner G, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003;52:1159-64.
8. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutation. J Pediatr 1995;127:705-10.
9. Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989;245:1066-73.
10. Ranieri E, Ryall RG, Morris CP, et al. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis. Br Med J 1991;302:1237-40.
11. Wilcken B, Wiley V, Sherry G, et al. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995;127:965-70.
12. Castellani C, Bonizzata A, Cabrini G, et al. Newborn screening strategy for cystic fibrosis: a field study in an area with high allelic heterogeneity. Acta Paediatr 1997;86:497-502.
13. Corbetta C, Seia M, Bassotti A, et al. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. J Med Screen 2002;9:60-3.
14. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (ΔF508). N Engl J Med 1990;323:1517-22.
15. Walkowiak J, Sands D, Nowakowska A, et al. Early decline of pancreatic function in cystic fibrosis patients with Class 1 or 2 CFTR mutation. J Pediatr Gastroenterol Nutr 2005;40:199-201.
16. Bonizzato A, Bisceglia L, Marigo C, et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. Hum Genet 1995;94:397-402.
17. Decaestecker K, Decaestecker E, Castellani C, et al. Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients. Eur Respir J 2004;23:679-84.
18. Dugueperoux I, De Braekeleer M. The CFTR 3849+10KbC->T and 2789+5G->A alleles are associated with a mild CF phenotype. Eur Respir J 2005;25:468-73.
19. Massie RJ, Wilcken B, Van Asperen P, et al. Pancreatic function and extended mutation analysis in ΔF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr 2000;137:214-20.
20. Cabrini G, Pederzini F, Perobelli L, et al. An evaluation of an enzyme assay method for immunoreactive trypsin in dried blood spots. Clin Biochem 1990;23:213-19.
21. Petterson K, Solderholm J, Suonpaa M. Organisation of an immunofluorometric assay based on the DELFIA technique for the measurement of immunoreactive trypsinogen in dry blood spots [abstract]. Pediatr Pulmonol Suppl 1991;7:90.
22. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23:544-9.
23. Pederzini F, Faraguna D, Giglio L, et al. Development of a screening system for cystic fibrosis: meconium or blood spot trypsin or both? Acta Pediatr Scand 1990;79:935-42.
24. Singer-Sam J, Tanguay RL, Riggs AD. Use of Chelex to improve the PCR signal from a small number of cells. Amplifications 1989;3:11.
25. Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 1991;10:506-13.
26. Gasparini P, Bonizzato A, Dognini M, et al. Restriction site generating polymerase chain reaction (RG-PCR) for the probeless detection of hidden genetic variation: application to the study of some common cystic fibrosis mutations. Mol Cell Probes 1992;6:1-7.
27. Rommens J, Kerem BS, Greer W, et al. Rapid nonradioactive detection of the major cystic fibrosis mutation. Am J Hum Genet 1990;46:395-6.
28. Chehab FF, Wall J. Detection of multiple cystic fibrosis mutations by reverse dot blot hybridization: a technology for carrier screening. Hum Genet 1992;89:163-8.
29. Wang L, Hirayasu K, Ishizawa M, et al. Purification of genomic DNA from human whole blood by isopropanol-fractionation with concentrated NaI and SDS. Nucleic Acids Res 1994;22:1774-5.
30. van de Kamer JH, Bokkel Huinick H, Weyers HA. Rapid method for the determination of fat in faeces. J Biol Chem 1949;177:347-55.
31. Jeejeebhoy KN, Ahmed S, Kozak G. Determination of fecal fats containing both medium and long chain triglycerides and fatty acids. Clin Biochem 1970;3:157-63.
32. Gaskin KJ, Durie PR, Lee L, et al. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhoea secondary to relative colipase deficiency. Gastroenterology 1984;86:1-7.
33. Gaskin KJ, Durie PR, Hill RE, et al. Colipase and maximally activated pancreatic lipase in normal subjects and patients with steatorrhoea. J Clin Invest 1982;69:427-34.
34. Peat J, Mellis C, Williams K, Xuan W, eds. Calculating the sample size. In: Health science research, a handbook of quantitative methods. Australia: Allen and Unwin, 2001:128-47.
35. Gaskin KJ, Gurwitz D, Durie P, et al. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr 1982;100:857-62.